GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Beneish M-Score

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Beneish M-Score : 9.74 (As of May. 01, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 9.74 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Arcturus Therapeutics Holdings's Beneish M-Score or its related term are showing as below:

ARCT' s Beneish M-Score Range Over the Past 10 Years
Min: -5.01   Med: 0   Max: 10.66
Current: 9.74

During the past 13 years, the highest Beneish M-Score of Arcturus Therapeutics Holdings was 10.66. The lowest was -5.01. And the median was 0.00.


Arcturus Therapeutics Holdings Beneish M-Score Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Beneish M-Score Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.79 -2.89 8.01 10.66 9.74

Arcturus Therapeutics Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.66 13.75 0.89 5.61 9.74

Competitive Comparison of Arcturus Therapeutics Holdings's Beneish M-Score

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Beneish M-Score falls into.



Arcturus Therapeutics Holdings Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Arcturus Therapeutics Holdings for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 15.1315+0.528 * 1+0.404 * 0.9443+0.892 * 0.7667+0.115 * 0.4875
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.4968+4.679 * -0.105612-0.327 * 0.7199
=9.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $32.1 Mil.
Revenue was 25.078 + 43.376 + 9.565 + 79.729 = $157.7 Mil.
Gross Profit was 25.078 + 43.376 + 9.565 + 79.729 = $157.7 Mil.
Total Current Assets was $386.6 Mil.
Total Assets was $429.4 Mil.
Property, Plant and Equipment(Net PPE) was $40.9 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.0 Mil.
Selling, General, & Admin. Expense(SGA) was $52.9 Mil.
Total Current Liabilities was $82.0 Mil.
Long-Term Debt & Capital Lease Obligation was $25.9 Mil.
Net Income was -11.707 + -16.222 + -52.55 + 50.754 = $-29.7 Mil.
Non Operating Income was -0.054 + 0.004 + 0.149 + 33.625 = $33.7 Mil.
Cash Flow from Operations was -0.629 + -32.406 + 50.807 + -35.871 = $-18.1 Mil.
Total Receivables was $2.8 Mil.
Revenue was 160.049 + 13.369 + 27.093 + 5.244 = $205.8 Mil.
Gross Profit was 160.049 + 13.369 + 27.093 + 5.244 = $205.8 Mil.
Total Current Assets was $403.3 Mil.
Total Assets was $450.4 Mil.
Property, Plant and Equipment(Net PPE) was $45.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.5 Mil.
Selling, General, & Admin. Expense(SGA) was $46.1 Mil.
Total Current Liabilities was $127.0 Mil.
Long-Term Debt & Capital Lease Obligation was $30.2 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(32.064 / 157.748) / (2.764 / 205.755)
=0.203261 / 0.013433
=15.1315

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(205.755 / 205.755) / (157.748 / 157.748)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (386.59 + 40.927) / 429.402) / (1 - (403.333 + 44.96) / 450.387)
=0.00439 / 0.004649
=0.9443

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=157.748 / 205.755
=0.7667

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.527 / (1.527 + 44.96)) / (2.957 / (2.957 + 40.927))
=0.032848 / 0.067382
=0.4875

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(52.871 / 157.748) / (46.071 / 205.755)
=0.335161 / 0.223912
=1.4968

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((25.907 + 81.989) / 429.402) / ((30.216 + 126.984) / 450.387)
=0.25127 / 0.349033
=0.7199

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-29.725 - 33.724 - -18.099) / 429.402
=-0.105612

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Arcturus Therapeutics Holdings has a M-score of 9.74 signals that the company is likely to be a manipulator.


Arcturus Therapeutics Holdings Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Headlines

From GuruFocus

Arcturus Appoints John Markels, Ph.D. to its Board of Directors

By Business Wire Business Wire 12-13-2022

Arcturus Therapeutics to Attend the Following Investor Conferences

By Business Wire Business Wire 09-01-2022